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Abstract Carriers of cytogenetically similar, apparently
balanced familial chromosome translocations not always
exhibit the putative translocation-associated disease pheno-
type. Additional genetic defects, such as genomic imbal-
ance at breakpoint regions or elsewhere in the genome,
have been reported as the most plausible explanation.
By means of comprehensive molecular and functional
analyses, additional to careful dissection of the t(3;14)
(q26.33;q12) breakpoints, we unveil a novel X-linked
PGK1 mutation and examine the contribution of these to
the extremely severe clinical phenotype characterized by
hemolytic anemia and neuromyopathy.
The 3q26.33 breakpoint is 40 kb from the 50 region of
tetratricopeptide repeat domain 14 gene (TTC14), whereas
the 14q12 breakpoint is within IVS6 of nucleotide-binding
protein-like gene (NUBPL) that encodes a mitochondrial
complex I assembly factor. Disruption of NUBPL in
translocation carriers leads to a decrease in the
corresponding mRNA accompanied by a decrease in
protein level. Exclusion of pathogenic genomic imbalance
and reassessment of familial clinical history indicate the
existence of an additional causal genetic defect. Conse-
quently, by WES a novel mutation, c.358G>A, p.E120K,
in the X-linked phosphoglycerate kinase 1 (PGK1) was
identified that segregates with the phenotype. Specific
activity, kinetic properties, and thermal stability of this
enzyme variant were severely affected. The novel PGK1
mutation is the primary genetic alteration underlying the
reported phenotype as the translocation per se only results
in a subclinical phenotype. Nevertheless, its co-inheritance
presumably exacerbates PGK1-deficient phenotype, most
likely due to a synergistic interaction of the affected genes
both involved in cell energy supply.
Introduction
There is an intriguing group of apparently balanced familial
chromosomal translocations characterized by phenotypic
inconsistency among carriers of cytogenetically similar
rearrangements.
The most fascinating explanation for this would be the
co-inheritance of the chromosomal translocation with a
mutation at the same or at a distinct genetic locus, leading
to a recessive monogenic or digenic disorder. Such a case
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has not yet been described so far (Sch€affer 2013). On the
contrary, genomic imbalance at breakpoint regions is the
most plausible explanation of such phenotypic inconsis-
tency observed among carriers of similar chromosomal
translocations (De Gregori et al. 2007).
Presently, the lack of a fully annotated human genome,
including a haploinsufficiency map, hinders predictability
of the phenotypic consequences of balanced chromosomal
translocations even when the breakpoints are identified at
nucleotide resolution. Although these may considerably
affect the genomic architecture at breakpoint regions, a
large majority are expected to be phenotypically impercep-
tible or subclinical. Nevertheless, otherwise subclinical
translocations may modulate clinical phenotypes.
In eukaryotes ATP synthesis relies on glycolysis and
oxidative phosphorylation (OXPHOS). Phosphoglycerate
kinase 1 (PGK1; ATP: 3-phosphoglycerate 1-phosphotrans-
ferase; EC 2.7.2.3) is a multifunctional protein with a key
role in ATP generation during glycolysis. PGK1 deficiency
(OMIM #300653) is an X-linked recessive condition
characterized by variable clinical manifestations involving
up to three different tissues, i.e., red blood cells (RBC),
skeletal muscle, and neurological tissue. However, patients
rarely show all three clinical features (Beutler 2007;
Chiarelli et al. 2012). To date, 22 different mutations have
been identified in PGK1, and 17 of them have been
characterized at the protein level (Chiarelli et al. 2012;
Fermo et al. 2012; Tamai et al. 2014).
Mitochondrial complex I (CI) or NADH-ubiquinone
reductase (EC 1.6.5.3) is part of the electron transport
chain that results in ATP synthesis through complex V or
ATP synthase of the OXPHOS pathway (Fassone and
Rahman 2012). At least 12 assembly factors are required
for the proper assembly, stability, or maturation of this CI
(Fassone and Rahman 2012). One of these assembly factors
is NUBPL, the depletion of which causes CI deficiency
(OMIM #252010) (Tucker et al. 2012; Kevelam et al.
2013). Incorporation of Fe/S clusters into CI subunits by
NUBPL is indispensable for electron transfer activity of CI
(Sheftel et al. 2009).
Here we present detailed molecular and functional
analyses demonstrating that the phenotype allegedly asso-
ciated with the chromosome rearrangement t(3;14)(q26.33;
q12) is actually due to a novel PGK1 variant, p.E120K,
resulting in severe decrease of enzyme activity and that
14q12 breakpoint disruption of mitochondrial CI assembly
factor, NUBPL, presumably exacerbates the neuromuscular
symptoms of the enzyme deficiency.
Materials and Methods
Samples, Cytogenetic Analysis, and Lymphoblastoid Cell
Lines (LCLs)
The family under study is from Hungary. Blood samples
were collected after informed consent; the study was carried
out according to the Principles of the Declaration of
Helsinki of the World Medical Association.
Cytogenetic analyses and the establishment of LCLs
were performed as previously described (David et al.
2009).
DNA extraction, flow sorting of derivative (der)
chromosomes, array painting, amplification of the junction
fragments, and SNP 6.0 array analysis
Genomic DNA extractions, flow sorting, and amplification
of der chromosome-specific DNAs were performed as
described earlier (David et al. 2009, 2013). Genomic
amplicons of der(3) and der(14) chromosomes were
analyzed by array painting using CytoScan HD array
(Affymetrix, Santa Clara, CA, USA). The der(3) and der
(14) junction fragments were amplified (see Table S1 for
conditions) and sequenced by Sanger sequencing.
Genomic DNA from the index subject and his brothers
(III:3 and III:6) was analyzed by Genome-Wide Human
SNP 6.0 array (Affymetrix). Genotype calling was carried
out using Genotyping Console software, and data was
visualized using the Chromosome Analysis Suite (ChAS)
software (Affymetrix).
Whole-Exome Sequencing (WES)
Exonic targets were captured and enriched using the
SureSelect Human All Exon 50 Mb Kit from Agilent
Technologies (Santa Clara, CA, USA) and sequenced on a
HiSeq2000 instrument (Illumina, San Diego, CA) following
the manufacturer’s instructions. Variants were annotated,
and known SNPs as well as novel genetic alterations were
identified.
RNA Extraction and Expression Studies
Extraction of RNA samples from LCLs and reverse
transcription (RT) reactions were performed as described
earlier (David et al. 2013). For real-time quantitative PCR
(RT-qPCR), see supplementary material.
Expression profiling of LCLs from the index subject and
III:3 was carried out using the Human Gene 1.0 ST
expression array (Affymetrix), and data analysis was
performed as previously described (David et al. 2013).
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Construction of the Expression Vector Coding for PGK1
p.E120K Variant
The vector encoding PGK1-E120K variant was obtained by
subjecting pMM1 to site-directed mutagenesis using Quick
Change XL site-directed mutagenesis kit (Stratagene, La
Jolla, CA, USA) (Chiarelli et al. 2012). Mutagenic
oligonucleotides are available in supplementary material.
Expression, Purification, and Characterization of the
PGK1-E120K Variant
The PGK1-E120K was expressed in E. coli BL21(DE3)
pLysS cells grown on ZYP-5052 autoinducing medium.
The expressed enzyme variant was purified essentially as
previously described (Chiarelli et al. 2012). Enzymatic
activity and kinetic and thermal stability analyses have been
performed (see the supplementary material).
SDS-PAGE and Immunodetection
SDS-PAGE analysis was performed in control and subjects’
LCL’s pellets (15 mg protein). For immunodetection the
following antibodies were used: rabbit anti-NUBPL (Mito-
sciences, Eugene, OR, USA), mouse anti-tubulin (Sigma,
St. Louis, USA), and MitoProfile Total OXPHOS antibody
cocktail (Mitosciences, Eugene, OR, USA). Quantification
was performed using the Quantity One (BioRad) software.
Results
Clinical Report
The first reported symptom of the index subject (Fig. 1,
III:5) was neonatal hyperbilirubinemia. Transfusion therapy
was necessary at the age of eight months because of severe
anemia, jaundice, and hepatomegaly, leading to the diagno-
sis of idiopathic hemolytic anemia. His dysmorphic features
resembled those of his affected brother III:4 (Supple-
mentary Material and Table S2), but, additionally, brachy-
cephaly, short neck, reduced length of phalanges, four-digit
crease on the right palm, cutaneous syndactyly II/III of the
feet, and severe hypotonia were also reported (Fig. S2C).
Repeated therapy-resistant seizures started at one year of
age, and his unconscious stage resulted in a suspected but
unconfirmed diagnosis of meningoencephalitis. Besides
epilepsy, one of the hemolytic events caused stroke and
hemiparesis of the left side. Cognitive and somatic
development of the child stopped at the age of one year
and 6 months: he did not walk and could not speak, but he
had no hearing loss. Swallowing difficulties became more
and more pronounced; gastrostoma and tube feeding were
initiated from the age of 2 years. Severe recurrent hemolytic
crises led to a partial splenectomy at the age of four and a
half years. Positron emission tomography revealed Ras-
mussen’s encephalitis at 5 years of age. At 6 years of age,
ketogenic diet was initiated.
At the age of thirteen years, in 2013, he presented total
body muscle atrophy, generalized somatic hypotrophy,
diminished joint movements, muscle contractures, severe
somato-mental retardation, no speech and no personal
contact with other individuals, multiple dental caries, and
bilateral cryptorchidism. The eyes are “swimming.”
Two of his brothers (Fig. 1, III:3 and III:6) are healthy.
In general, psychomotor development of III:3 was normal.
He did not present any dysmorphic features. Reportedly,
with physical effort, he shows signs of weakness and
premature fatigue, well before his age-matched coworkers
(Table 1).
Both parents are healthy, but the mother (II:5), in
addition to anemia during pregnancies, also presents signs
of fatigue.
During the course of this study, a maternal male cousin
(Fig. 1, III:2), who died after falling down the stairs at the
age of 7 years, was reported to have symptoms similar to
his cousins.
His mother (II:3) and the remaining relatives (I:2, II:1,
III:1) are all healthy. For additional clinical description,
including subjects III:4 and III:2, see supplementary material.
Cytogenetic Analysis
Cytogenetic analysis of GTL-banded metaphase chromo-
somes performed on subject III:4 revealed an apparently
balanced reciprocal chromosome translocation between the
long arms of chromosomes 3 and 14 [46,XY,t(3;14)(q26.3;
q12)] (Fig. S2A and B). Furthermore, his healthy mother
(II:5) and two of his brothers (III:3 and III:5) were also
carriers of a similar translocation (Fig. 1a).
No perfect co-segregation between the translocation and
the reported phenotype could be observed; therefore, we
hypothesized that an additional genomic or genetic defect
might also segregate in this family.
Breakpoints and Candidate Genes
Genomic amplicons of flow-sorted der chromosomes were
analyzed by array painting, and the breakpoints were
narrowed to few kb regions (data not shown). Primers
flanking the predicted breakpoints were designed, and the
junction fragments were amplified and sequenced (Table
S1). The alterations revealed by sequence alignments of the
junction fragments are summarized in Fig. S1.
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The 3q26.33 breakpoint is at position g.180,278,286_
180,278,294delTTCTGCA, 41.6 kb upstream of the 50
region of tetratricopeptide repeat domain 14 (TTC14), a
gene whose function is presently unknown (Fig. S3).
Additional genes localized further distal from the break-
point are (1) the coiled-coil domain containing 39
(CCDC39) localized only at 53.5 kb, (2) the FXR1, and
(3) the DnaJ (Hsp40) homologue, subfamily C, member 19
(DNAJC19). This gene encodes an important protein for
mitochondrial physiology. Located at the inner mito-
chondrial membrane, it has been shown to function as a
chaperone for mitochondrial protein import system.
Defects in this gene are reported to cause an autosomal
recessive secondary 3-methylglutaconic aciduria (OMIM
#610198), a disorder that partially overlaps with that of
reported subjects (Table 1) (Wortmann et al. 2012, 2013;
Table 1 Clinical features in subject carriers of either the PGK1 c.358A mutation or the t(3;14) translocation alone or in association
Clinical features
III:2 PGK1
c.358A
III:4 PGK1
c.358A&t(3;14)
III:5 PGK1
c.358A&t(3;14) III:3 t(3;14)
NUBPL
a252010
CCDC39
a613807
DNAJC19
a610198
Hemolytic anemia Severe Severe Severe No NR NR Normochromic
microcytic
Erythroblastosis
fetalis
Yes Yes Yes No – – NR
Jaundice Yes Yes Yes No – – NR
Hyperbilirubinemia Yes Yes Yes No – – NR
Hemolytic crisis Severe Severe Severe No – – NR
Hepatosplenomegaly Yes Yes Yes No – – NR
Splenectomy ND No Yes No – – NR
Hemoglobin Decreased Decreased Decreased No – – NR
MCV Normal Decreased Decreased No – – Decreased
Neurological
dysfunction
Yes Yes Yes No Characteristic NR Described
Neonatal hypotonia No Yes Yes No – – NR
Developmental delay Moderate Yes Yes No Characteristic – Described
Intellectual disability Mild Severe Severe No Described – Described
Speech Delayed Absent Absent Normal Described – Reported
Seizures, epilepsy Severe Severe Severe No Reported – NR
Encephalopathy Yes Yes Yes No Described – NR
Ataxia NR NR NR Transient Described – Reported
Myopathy Yes Yes Yes No Characteristic NR Cardiomyopathy
Muscular dystrophy No Severe Severe No – – –
Weakness Yes Yes Yes Yes Yes – Yes
Unsupported walking Walk with
help
Never sit or
walk
Never walked No Characteristic – Characteristic
Spastic muscular tone Yes Yes Yes No Described – –
Nuchal and dorsal
muscle hypotonia
Yes Yes Yes No – – –
Swallow, tube
feeding
Yes Yes Yes No Described – –
Horizontal nystagmus Unknown Yes Yes No Characteristic – Reported
Infection Repeated Repeated Repeated No – Characteristic –
a OMIM number
NR not reported (see also Table S2)
Fig. 1 (continued) Pedigree of the family, WES, and confirmation
of the X-linked PGK1 c.358G>A, p.E120K mutation. (a) Pedigree
illustrating the segregation of the t(3;14)(q26.3;q12) and PGK1
mutation. The index patient is indicated by asterisk. Translocation
carriers are shown as hatched or half-hatched symbols, whereas filled
and half-filled symbols denote the segregation of PGK1 mutation.
Data in parentheses are inferred. The ratio of X-chromosome
inactivation of PGK1 mutation carrier females is indicated (Xa:
active X chromosome). (b) Alignment of WES reads visualized using
IGV tool indicating the homozygous single base substitution in exon
4 of PGK1. (c, d) Confirmation of the missense mutation c.358G>A;
p.E120K by Sanger sequencing in subjects II:5 and III:5
◂
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Davey et al. 2006). Therefore, serum and urine amino acid
and urine organic acid levels were determined (see Table
S3A and S3B). In subject III:3, 3-hydroxybutyric acid was
especially increased, but also 3-methylglutaconic acid (3-
MGA) and 3-methylglutaric acid (3-MG) were slightly
increased.
The 14q12 breakpoint is at position g.32,248,943_
32,248,944dupATAAGATAACAAG, within IVS6 of
NUBPL (Fig. 2), a member of the Mrp/NBP35 ATP-
binding protein family, and critical for the assembly of
human respiratory mitochondrial CI (Sheftel et al. 2009).
Recently, recessive mutations in NUBPL have been
implicated in the genetic etiology of CI deficiency [OMIM
#252010], a mitochondrial respiratory chain defect that is
caused by mutations in multiple different nuclear, mito-
chondrial, or X-linked genes (Calvo et al. 2010; Fassone
and Rahman 2012). Additionally, in subjects with pediatric
neurological disorders, three deletions encompassing this
gene were reported (p ¼ 0.135) (Cooper et al. 2011).
Exclusion of Genomic Imbalance and Identification of the
Additional Genetic Defect
Pathogenic genomic imbalance that could explain the
phenotypic inconsistency observed among translocation
carriers was excluded by SNP 6.0 array analysis.
Subsequently, reevaluation of the family history revealed
that the maternal cousin (III:2; Fig. 1a) presented a clinical
phenotype resembling that of index subject. Based on this,
two possible disorders, X-linked PGK1 and triosephosphate
isomerase 1 (TPI1; OMIM #190450, 12p13.31) deficiencies,
were suggested. Furthermore, X-chromosome segregation
analysis among siblings using array-based SNP data corro-
borated the possibility of PGK1 deficiency (data not shown).
Fig. 2 Overview of the chromosome 14q12 breakpoint region. (a)
Schematic ideogram of chromosome 14; the breakpoint region is
highlighted by a box. (b) Array analysis of the 14q12 breakpoint
region using the Genome-Wide Human SNP array 6.0. A dashed line
highlights the position of the breakpoint; Log2 ratios and allele
differences are shown from the region (each dot point represents an
oligonucleotide probe). Below, genes within this interval are depicted.
No genomic imbalance can be identified within this region. (c)
Detailed physical map across the breakpoint region. Horizontal lines
with folded gray arrows indicate the position of genes in sense (above
the map) and antisense (below the map) orientation. (d) Detailed map
of NUBPL (RefSeq NM_025152.2) indicating the position of break-
point at nucleotide resolution and the positions of TaqMan gene
expression assay probe
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Consequently, WES of the index subject revealed a novel
missense mutation c.358G>A that leads to a change from
glutamic acid to lysine at position 120 of PGK1 (p.E120K)
within exon 4 (Fig. 1b). Segregation study confirmed this
alteration in the index subject and showed that female
subjects I:2, II:3, and II:5 are asymptomatic carriers (Fig. 1a,
c and d), whereas the remaining family members are normal.
Substitution of the highly conserved, solvent-exposed,
negatively charged glutamic acid 120 by positively charged
lysine (E120K; Table S7, Figs. S4 and S7) increases the net
charge of the protein by two units (from 2.8 to 4.8 at pH 7.4)
and certainly strongly argues in favor of this being the
disease-causing mutation.
Borderline skewed X-chromosome inactivation toward
the normal allele (25:75) was observed in female II:5, the
only mutation carrier that presented symptoms during
pregnancy (data not shown).
Functional Characterization of the PGK1 p.E120K Variant
The specific activity of the purified PGK1-E120K variant
was 10.2 U/mg compared to that of 816 U/mg of PGK1-
WT (Chiarelli et al. 2012).
Kinetic analysis showed that, like PGK1-WT, PGK1-
E120K variant was activated by high substrate concen-
trations (Fig. 3a and b) (Chiarelli et al. 2012). The mutant
enzyme turned out to be severely affected in its kinetic
properties (Table S4), showing a reduction of two orders of
magnitude of its apparent kcat values toward both substrates.
The apparent Km value toward 3-PG was sevenfold
increased with respect to that of PGK1-WT, whereas that
toward Mg-ATP was practically unchanged.
Interestingly, the variant’s thermal inactivation rate
curve was biphasic, with an increased slope after 5 min
incubation, suggesting that it underwent heat-induced
molecular change leading to the loss of enzyme activity
(Fig. S5).
Gene Expression Studies
Expression array profiling of LCLs from translocation
carriers (only one of them affected by the PGK1 mutation)
did not reveal significantly altered expression of genes from
the breakpoints (Table S5). The expression level of the
disrupted NUBPL was only reduced by ~1 SD.
Subsequently, expression levels of three of these genes
were also analyzed in subjects II:5, III:5, III:3, III:6, and
controls by RT-qPCR (Fig. 4a, Table S5, Fig. S6A and B).
By this analysis, a statistically significant 2.6-fold reduction
of the NUBPL expression level (P ¼ 0.0001; 0.061 vs.
0.156) was observed.
Additionally, systematic analysis of array expression
data of mitochondrial CI subunits did not show consider-
able alteration in their expression (Table S6).
SDS-PAGE Western Blot Analysis
Levels of the five OXPHOS complexes as well as the
NUBPL assembly factor were determined by SDS-PAGE
Western blot in LCLs, as our attempt to establish a
fibroblast cell line from the index subject was unsuccessful.
NUBPL levels were reduced in all translocation carriers
although at different extent (Fig. 4b). No significant
changes were observed in the levels of the five complexes
Fig. 3 Kinetic profile of PGK1-E120K variant vs. wild-type enzyme.
Steady-state kinetics of PGK1-E120K variant and wild-type as
function of (a) Mg-ATP at fixed 5 mM 3-PG concentration and (b)
as of 3-PG at fixed 5 mM Mg-ATP concentration. Open circles
represent the PGK1-E120K variant, whereas filled circles represent
the wild type. Like the wild type, the PGK1-E120K variant presents a
biphasic kinetic behavior toward the two substrates; therefore, the
linear region (0–5 mM substrates, range of physiological concentra-
tion) was considered to extrapolate the kinetic parameters
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by the OXPHOS antibody cocktail (Fig. 4c). The dissimilar
reduction of NUBPL protein in translocation carriers is in
striking contrast with the evenly reduced mRNAs levels
(Fig. 4a).
Discussion
Alleged association of the familial translocation t(3;14)
(q26;q12) with a particularly severe hemolytic anemia and
neuromyopathy led us to map the translocation breakpoints,
at nucleotide resolution.
Given the absence of genomic imbalance that could
explain the phenotypic inconsistency observed among
translocation carriers, and taking into account previously
unreported family medical history data, the presence of an
additional genetic defect was hypothesized. Segregation
analysis of X chromosome and WES revealed that the
index subject is also affected by a novel X-linked PGK1
mutation (c.358G>A, p.E120K) within a highly conserved
region.
Biochemical and functional characterization of the
PGK1-E120K variant showed highly perturbed kinetic
properties (Table S4). Very likely the p.E120K substitution
Fig. 4 Quantification of NUBPL mRNA and protein in LCLs of
translocation carriers and controls. (a) Bar graph depicting the relative
expression of the NUBPL transcript comprising the exon 8–9 junction.
Expression levels were normalized to the internal control (DIDO1).
Fold change relative to reference is given in 2DCt. Error bars
represent standard deviation, and C1 to C13 are control LCLs from
unrelated subjects. (b) SDS-PAGE Western blot of NUBPL and alpha
tubulin (loading control) in the family members and control LCLs
showing significant reduction of NUBPL in the individuals affected
by the translocation. NUBPL expression levels were normalized to the
loading control. (c) SDS-PAGE Western blot of MitoProfile Total
OXPHOS Human WB antibody cocktail
62 JIMD Reports
leads to a distorted local protein structure with detrimental
indirect effect on the active site geometry, locking the
enzyme in a more tight conformation and hindering proper
domain movements required for its catalytic activity.
Additionally, the variant turned out to have weakened
protein stability (Fig. S4) most likely due to an intrinsic
propensity of aggregating in a temperature- and time-
dependent manner (Pey et al. 2013). These data led us to
conclude that p.E120K is one of the most severely impaired
PGK1 variants characterized thus far (Fermo et al. 2012;
Chiarelli et al. 2012) and consequently the main genetic
cause of the phenotype observed in this family.
Although rare, lethal forms of PGK1 deficiency during
infancy have been reported in the literature (Beutler 2007).
Even more infrequent are PGK1-deficient patients exhibit-
ing the three distinguishing clinical features of this
deficiency (hereditary non-spherocytic hemolytic anemia,
neurological dysfunction, and myopathy). In the family
reported here, all affected subjects (III:2, III:4, and III:5)
presented the full clinical spectrum of PGK1 deficiency,
and seemingly they are among the most severely affected
PGK1-deficient patients reported to date.
The disruption of NUBPL by the 14q12 breakpoint led to
a 60% reduction of the mRNA expression level of this CI
assembly factor in three family members. Concomitant
reduction of the protein level was also observed, being the
index subject, the most affected one. The translocation per
se is only associated with a subclinical state as the only
clinical feature reported in translocation carriers (without
PGK1 deficiency) is exercise intolerance due to premature
fatigue, a common symptom of mitochondrial myopathy.
Interestingly, homozygous subjects for the branch-site
mutation c.815-27T>C within IVS 9 of NUBPL are
predicted to have ~30% of NUBPL expression. This
mutation was excluded in the presently reported family
(data not shown). The partially impaired CI function in these
subjects is also sub-pathologic and certainly not associated
to a mitochondrial CI disease (Tucker et al. 2012).
Although generally the clinical phenotype of family
members carrying identical PGK1 mutations is reportedly
similar, both translocation carriers (III:4 and III:5), unlike
their translocation noncarrier cousin, show severe neuro-
myopathy with exacerbated muscular dystrophy.
In different tissues or pathogenic conditions, one of the
two metabolic pathways, glycolysis or OXPHOS, is
predominant over the other (Hu et al. 2012). Additionally,
these pathways are interconnected as cytosolic NADH, the
electron supplier that drives ATP synthesis via OXPHOS, is
generated through glycolysis to pyruvate by glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) [see Glycolysis:
Regulating Blood Glucose, http://themedicalbiochemistry-
page.org/glycolysis.php] (Ramzan et al. 2013). Synergistic
interactions, called synergistic heterozygosity, between
defects in one or more different energy metabolism path-
ways have been reported as a common disease mechanism
(Vockley et al. 2000). Such interaction between the reported
genetic defects, both participating in cellular energy meta-
bolism, seems obvious.
Although unlikely, we cannot exclude that other genes
from the breakpoint regions, such as DNAJC19, may also
contribute to the increased clinical severity of PGK1
deficiency in translocation carriers. The slight increase of
both 3-MGA and 3-MG observed in the index subject can
be related with several features of the clinical phenotype
(metabolic disorder, mitochondrial dysfunction, progressive
neuromuscular degeneration, and anemia) (Wortmann et al.
2013). Additionally, glycogen granules and granular struc-
tures in the mitochondria of endothelial cells and muscle
fibers were reported in a PGK1-deficient subject (Schr€oder
et al. 1996). Therefore, involvement of PGK1 deficiency in
mitochondrial dysfunction seems likely and can also be
related to the drastic reduction of NUBPL in the index
subject.
Even more unlikely, but theoretically possible, is that the
observed phenotype is exclusively the result of the novel
PGK1 mutation, and the phenotype heterogeneity observed
among translocation carriers and noncarriers is the outcome
of each individual’s genomic/epigenetic background.
In conclusion, the discordant inheritance of the allegedly
translocation-associated severe phenotype, instead of being
due to a genomic imbalance, is mainly explained by
independent inheritance of a novel PGK1 c.358G>A, p.
E120K mutation. The pathogenicity of this mutation was
confirmed by in vitro functional characterization of the
variant. Furthermore, the t(3;14)(q26;q12) is only associated
with a subclinical phenotype; nevertheless, disruption
NUBPL, a component of the OXPHOS cellular energy
pathway, most likely exacerbates the PGK1-deficient phe-
notype in subjects who are also translocation carriers. In
addition, the case presented here constitutes a “beautiful”
example of synergistic heterozygosity and a naturally
occurring model to study the interactions between cellular
energy pathways and their association with mitochondrial
dysfunction. Therefore, further studies are warranted to
clarify these additional aspects.
Additionally our data imply that synergistic interactions,
involving heterozygous genomic and chromosome re-
arrangements, may contribute for the “missing” heritability
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of inborn metabolic disorders. Last but not least, this study
eloquently illustrates that even in our genomic era with
WES and personalized genomics, a thorough family medical
history is necessary in the elucidation of the molecular bases
of rare diseases and their prevention.
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Synopsis
An extremely severe non-spherocytic hemolytic anemia and
neuromyopathy, hypothesized to be associated with chro-
mosome translocation-associated genomic imbalance, were
shown to be mainly caused by a novel pathogenic severe
PGK1 mutation and that the neuromyopathic symptoms of
the deficiency are likely exacerbated by the disruption of
mitochondrial complex I assembly factor, NUBPL.
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Supplementary Material 
Materials and methods 
Analysis of WES, amplification and segregation analysis of the PGK1 mutation 
Mapping of the sequence reads was carried out by the Burrows-Wheeler Alignment tool 
(BWA) (Li and Durbin, 2009). For identification of single-nucleotide variants (SNVs) and 
small insertions / deletions the BWA alignment output SAM file (Sequence Alignment/Map) 
was further analyzed by SAMtools software package (Li et al, 2009). 
Amplification of PGK1 (RefSeq NM_000291.3) exon 4 from genomic DNAs was carried 
out using primers described in Table S1. 
Confirmation of the novel PGK1 mutation identified by WES and segregation analysis in 
available family members was performed by Sanger sequencing as described earlier (David et 
al, 2009). 
X-chromosome inactivation assay 
X-chromosome inactivation patterns in female carriers of the PGK1 mutation were assayed 
according to Kiedrowski and co-workers (Kiedrowski et al, 2011). 
Gene expression studies by real-time quantitative PCR (RT-qPCR) 
Expression level of three genes from the breakpoint regions were also analyzed using 
TaqMan gene expression assays. Namely, assay Hs00228512_m1, for exon 8 to 9 junction of 
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the disrupted NUBPL; assay Hs00750732_s1, for exon 2 of Rho GTPase activating protein 5 
(ARHGAP5) and assay Hs01096865_m1, for exon 2 to 3 junction of fragile X mental 
retardation, autosomal homolog 1 (FXR1). Death inducer-obliterator 1 (DIDO1; assay 
Hs00223101_m1) was used as internal control. 
All RT-qPCR reactions were performed in triplicate on an ABI 7000 Sequence Detection 
System (Applied Biosystems, Foster City, USA). The system’s default PCR conditions were 
used with 40 cycles. Data and statistical analysis were performed as previously described 
(David et al, 2013). 
Expression, purification and characterization of the PGK1-E120K variant 
The following mutagenic oligonucleotides were used : 
5’ CTGTCATCCTGCTGAAGAACCTCCGCTTTC 3’ and 
5’ GAAAGCGGAGGTTCTTCAGCAGGATGACAG 3’, respectively (the mutated 
nucleotides are underlined). The variant cDNA was completely sequenced. 
In order to remove protein aggregates, from the purified enzyme variant, a size exclusion 
chromatographic step on a 16/60 Superdex 75 column (GE Healthcare, Buckinghamshire, 
UK) equilibrated with 20 mM Tris pH 8.0, 1 mM EDTA, 2mM β-mercaptoethanol, 200 mM 
NaCl was included (Chiarelli et al, 2012; Pey et al, 2013). 
The enzyme activity of PGK1-E120K was measured at 37°C by glyceraldehyde 3-
phosphate dehydrogenase (GAPDH)-coupled spectrophotometric assay following the method 
recommended by the International Committee for Standardization in Hematology (Chiarelli et 
al, 2012). The standard reaction mixture contained 100 mM Tris pH 8.0, 0.5 mM EDTA, 2 
mM MgCl2, 0.24 mM NADH, 0.4 µM GAPDH, 5 mM Mg-ATP and 5 mM 3-
phosphoglycerate (3-PG), in a final volume of 0.5 ml. The reaction was started by adding 
enzyme solution (0.1-0.5 µg).  
Kinetic analyses were performed by assaying the enzyme activity at ten different 
concentrations of 3-PG and Mg-ATP in the presence of 5 mM Mg-ATP and 5 mM 3-PG, 
respectively. The reaction conditions were identical to those described above. All 
measurements were performed in triplicate by using a Jasco V-550 UV/VIS 
spectrophotometer (Jasco, Cremella, Italy). Kinetic parameters were calculated as previously 
described using SigmaPlot software version 12.0 (IBM SPSS, Inc., Chicago, IL, USA) 
(Szilágyi and Vas, 1998). 
For thermal stability studies, residual enzyme activity was assayed at different time-
points after incubation of purified enzyme (0.7 mg/ml) at given temperatures (Chiarelli et al, 
2012). 
SDS-PAGE and immunodetection 
Control and subjects’ LCL’s pellets were lysed in 200 μl homogenization buffer (150 mM 
NaCl, 1% NP-40 and 5 mM Tris/HCl, pH 8.0). Equal amounts of protein (15 μg) and a 
Precision Plus Protein Standards (BioRad, Hercules, CA, USA) were loaded and separated in 
SDS-PAGE gels (NuPAGE Novex 4-12% Bis-Tris gels; Invitrogen, Carlsbad, CA, USA). 
Gels were blotted to a PVDF transfer membrane (Immobilion-P, Millipore, Tullagreen, 
Ireland). Membrane was blocked with 5% skimmed milk and 0.05% Tween-20 in Tris-
buffered saline (TBS) for 1 h at room temperature and incubated with primary antibodies, 2h, 
at room temperature. The following specific antibodies were used: rabbit anti-NUBPL, 
(Mitosciences, Eugene, OR, USA), mouse anti-tubulin (Sigma, St. Louis, USA) and 
MitoProfile Total OXPHOS antibody cocktail containing antibodies against: complex I 
subunit NDUFB8, complex II subunit 30 kDa, complex III subunit Core 2, complex IV 
subunit II and ATP synthase subunit alpha (Mitosciences, Eugene, OR, USA). Membranes 
were then washed three times with 0.05% Tween-20 in TBS, incubated with the appropriate 
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peroxidase-conjugated IgGs secondary antibodies (GE Healthcare) for 1 h at room 
temperature and developed using Clarity Western ECL Substrate (BioRad). Quantification 
was performed using the software Quantity One (BioRad). 
 
Results 
Clinical reports 
Subject III:4 (Fig. 1) 
Subject III:4 (Fig. 1A) is the first known affected case in the family, the second (male) child 
of unrelated, apparently healthy parents. The newborn presented with hepato-splenomegaly 
and erythroblastosis fetalis, with a mild jaundice that did not require any exchange 
transfusion. At the end of the first week, generalized spastic muscle tone, nuchal and dorsal 
muscle hypotonia were observed. 
First hospital admission occurred at the age of one and a half months because of severe 
anemia, requiring blood transfusions. At the age of two months, the following dysmorphic 
signs were observed: moderate microcephaly, hypertelorism, epicanthal folds, broad nasal 
bridge, high arched palate, asymmetric face, fronto-occipital cranial elongation, low–set ears, 
short and pointed nose, frontal bossing, (see Table S2). Repeated infections of the respiratory 
tract, hemolytic episodes and severe general dystrophy during the first year of life made 
hospital admissions and blood transfusions at every second month necessary. Tonic-clonic 
seizures occurred for the first time at the age of twenty months. The neurological evaluations 
led to diagnosis of epilepsy. Increased muscle tone, especially of lower limbs and permanent 
horizontal nystagmus were obvious. He never sat up or walked and his weight gain stopped. 
Epileptic seizures became more and more frequent and he had difficulties in swallowing 
therefore tube feeding was initiated. He died at the age of four and a half years. 
Peripheral blood cell analysis revealed low red blood cells (RBC) count (1.9×10
12
/L), 
hematocrit (HCT: 0.20) and decreased hemoglobin (61 g/L). Mean corpuscular volume 
(MCV) was decreased (65μm3), whereas mean cell hemoglobin (MCH) and mean corpuscular 
hemoglobin concentration (MCHC) values were in normal range. Reticulocyte count was 98 
‰. Bone marrow contained normal amount of cells with slightly increased erythropoiesis and 
normal myelopoiesis. Coombs test and hemoglobin electrophoresis, were found as normal. 
Serum iron, ferritin levels, as well as total iron–binding capacity (TIBC), serum and 
erythrocyte folate and vitamin B12 levels were as in age-matched controls. Based on shorter 
erythrocyte lifespan (26 days), decreased osmotic resistance (0.40) and increased 
permeability, the diagnosis of intrinsic hemolytic anemia was established. 
In this period, significant decrease of plasma alkaline phosphatase activity, 10 IU/L, was 
observed (normal range for child 50-100 IU/L). 
Cardiovascular malformation and pathologic meningeal symptoms were not detected. 
Diagnostic imaging methods did not reveal any structural abnormality of the brain. 
Index subject III:5 (Fig. 1) 
Blood tests repeatedly showed major increase in creatine phosphokinase (CPK), 60,000 IU/L 
(normal range for children 50-100 IU/L) as well as of lactate dehydrogenase (LDH), 5,000 
U/L, (normal range for children 154-605). At 6 years of age ketogenic diet was initiated. 
Cardiac echography and ECG, as well as abdominal ultrasonography resulted in normal 
findings. No pathologic alteration could be found by audiometric hearing tests. At 11 years of 
age, sex hormone levels are similar to age-matched prepubertal boys. 
Subject III:2 (Fig. 1) 
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After the parents’ informed consent, his hospital records were studied. Indeed, he presented 
mental retardation, severe hemolytic anemia and seizures. Repeated infections and hemolytic 
crisis required frequent hospitalization and blood transfusions. At two years of age, he was 
treated for encephalopathy and liver damage. At six years of age, neurological evaluation was 
done because of coma and clonic–tonic seizures, resulting in diagnosis of therapy-resistant 
epilepsy. Owing to swallowing difficulties tube feeding was also initiated from the age of two 
years. There was a main difference compared to his cousins; he was able to walk with help 
and he presented generalized edema throughout the whole body. His mother (II:3), although 
operated because of a thrombotic accident, is healthy. The remaining relatives (I:2, II:1, III:1) 
are also healthy. 
Normal findings have been reported at cardiac examination and echocardiography. 
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Supplementary Figures 
 
Figure S1. Nucleotide sequence of der(3) and der(14) breakpoints aligned against the 
reference sequence. (A) Derivative chromosome 3 breakpoint. The chromosome 3 sequence is 
in black, whereas of chromosome 14 in gray. Vertical lines indicate identical nucleotides 
between derivative and reference chromosomes. The seven nucleotide (TTCTGCT) deletion 
from the chromosome 3 sequence is boxed, whereas the dinucleotide insertion (AG) at the 
der(3) breakpoint is in blue lowercase letters. (B) Derivative chromosome 14 breakpoint. The 
a 13 bp duplication (ATAAGATAACAAG) is in blue lowercase letters; the homologous 
sequence is underlined with solid and dotted lines, whereas those (GACTT) between 
chromosomes 3 and 14 (GACTT) by double line (reference human genome assembly 
GRCh37/hg19). 
The translocation could be defined as 
 [GRCh37/hg19]t(3;14)(3pter/3q26(+)(180,278,286)::AG::14q12(+)(32,248,944)14qter; 
14pter/14q12(+)(32,248,943)::ATAAGATAACAAG::(+)(180,278,294)/14qter) (Ordulu et al, 
2014). 
NCBI-GenBank accession numbers of the junction fragment sequences are KJ862055 and 
KJ862056, respectively. 
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Figure S2. Ideograms, partial karyotype and clinical phenotype of the index subject. 
(A) Ideograms illustrating the derivative chromosomes. (B) Partial karyotype showing the 
balanced familial translocation t(3;14)(q26.3;q12)] (♦ indicates the chromosome breakpoints). 
(C) Clinical details of the index subject (III:5) - moderate microcephaly, short neck, fronto-
occipital cranial elongation, frontal bossing, asymmetric face, hypertelorism, “swimming” 
eyes, epicanthal folds, broad nasal bridge, short nose, low-set dysplastic ears, total body 
muscle atrophy, muscle contractures, multiple dental caries (see Table S2).  
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Figure S3. Overview of the chromosome 3 breakpoint region. (A) Schematic ideogram of 
chromosome 3; the breakpoint region is highlighted by a box. (B) Array analysis using the 
Genome-Wild Human SNP array 6.0 from Affymetrix containing 1.8 million markers, 
(approximately 906,600 SNP and 946,000 copy number probes). Log2 ratios and allele 
differences are shown indicating the absence of genomic imbalance within this chromosome. 
(C) Detailed physical map across the breakpoint region. Horizontal lines with folded grey 
arrows indicate the position of genes in sense (above the map) and antisense (below the map) 
orientation. The position of the breakpoint at nucleotide resolution is specified and indicated 
by vertical arrow (nomenclature: cytogenetic position of the breakpoint; breakpoint at 
nucleotide resolution according to the reference chromosome on the positive strand; deleted 
sequence at the breakpoint; genome reference numbers). Bellow, horizontal lines denote BAC 
clones used as FISH probes. The hybridization signals and the corresponding GeneBank 
sequence acc. no. are annotated below the clones. 
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Figure S4. Alignment of the human PGK1 peptide sequence containing the amino acid 
substitution E120K with corresponding region of PGK from different species. The amino acid 
numbering of PGK1 starts with methionine. The dark grey zone indicates highly conserved 
region containing the mutated residue E120K (↓) and the 3-PG substrate binding residue 
R123 (○), just three amino acids downstream from the mutated one (Vas et al, 2010). 
Residue E120 is located on the short loop that follows β-strand D (Fig. S7). Residues 
belonging to the β-strand D are indicated by the black rectangle. 
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Figure S5. Thermal stability of wild-type and variant PGK1. Heat stability of PGK1-E120K 
variant (□) at 37°C and 45°C compared to wild-type enzyme (○). Thermal stability was 
measured by incubating the enzyme (0.7 mg/ml) at the given temperatures in a solution 
consisting of 20 mM Tris pH 8.0, 1 mM EDTA, 2mM β-mercaptoethanol. Samples (10 µl) 
were removed at intervals, chilled in ice and immediately assayed according to the published 
method (Chiarelli et al, 2012). Relative activity was calculated as the percent of the enzyme 
activity before the incubation. Fill symbols represent data points obtained at 37°C, open 
symbols at 45°C. 
The mutant enzyme lost 50% of its activity after 36 minutes of incubation at 37°C, whereas at 
45°C the half time was nearly 6 min. 
The variant’s thermal inactivation rate at 45°C accounts for an increased heat induced 
aggregation, as supported by the fact that samples treated at 45°C become more turbid with 
time. On the other hand, the freshly purified enzyme formed aggregates just after few hours of 
storage at 4°C. 
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Figure S6. Relative expression levels of two genes from the breakpoint regions in LCLs of 
family members and controls. (A) Bar graph depicting the relative expression of the 
ARHGAP5 exon 2 transcript. (B) Bar graph depicting the relative expression of the FXR1 
transcript comprising the exon 2-3 junction. Expression levels of both fragments were 
normalized to the internal control DIDO1. Fold change relative to reference is given in 2
Δ
Ct. 
Error bars represent standard deviation and C1 to C13 are control LCLs from unrelated 
subjects. 
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Figure S7. Ribbon representation of the human PGK1 protein structure. Three-dimensional 
structure of open (A, Protein Data Base entry 2XE7) and closed (B, Protein Data Base entry 
2WZC) human PGK1 associated with Mg-ADP and 3-PG.  
PGK1 is a typical hinge-bending monomeric enzyme containing two nearly equal-sized 
domains, separated by a deep cleft and linked by two α-helices. The N-domain binds 3-PG or 
1,3-BPG whereas the C-domain binds Mg-ADP or Mg-ATP. The enzyme can exist in 
different conformational structures induced by ligands. To perform the catalytic reaction 
PGK1 has to cycle from an open form to a closed one. The domain closure requires the 
concerted action of both substrates. The black arrows indicate the E120 amino acid 
represented as ball and stick and the β-strand D of the N-domain. Residue E120 locates in the 
loop immediately after the β-strand D and both structural elements are involved in 
interdomain interactions (Balog et al, 2007). Alpha-helixes are represented as cartoon in red 
while beta-sheets are in blue; Mg-ADP and 3-PG are shown as black stick models. 
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Supplementary Tables 
 
Table S1. Primers and amplification conditions used for breakpoint mapping, amplification of junction fragments and of exon 4 of 
PGK1 
PCR fragment Designation Primer sequence (5’-3’) aPrimer localization Annealing T (°C) PCR size (bp) 
Junction fragments     
der(3) junction 
fragment 
AC125618-fjF1 TAACATTGAAGATGGCCGAAC 180,277,714-180,277,733 
61 787 
AL359400-fjR2 CCAGCTTTTCAGGGAGTGAAT   32,249,156-32,249,136 
der(14) junction 
fragment 
AL359400-fjF1 GCTGGCTTATGATGTGACTTGA   32,248,590-32,248,611 
61 862 
AC125618-fjR1 TTCAGCTTTTCTGCTCTGGTTT 180,278,788-180,278,767 
PGK1 exon 4 
PGK1Ex4-F TGGTGCTGGTAGACTTTGTGG 77,369,412-77,369,432 
62 379 
PGK1Ex4-R AAGCTGTGTCGGCATTGTATG 77,369,790-77,369,770 
a
Numbers indicate the position of the primers in the current genome assembly (GRCh37/hg19). 
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Table S2. Dysmorphic features in subjects carriers of either the PGK1 c. 358A mutation or the t(3;14) translocation alone or in association 
Clinical features 
III:2 PGK1 
c.358A 
III:4 PGK1 
c.358A & t(3;14) 
III:5 PGK1 
c.358A & t(3;14) 
III:3 
t(3;14) 
NUBPL 
a
252010 
CCDC39 
a
613807 
DNAJC19 
a
610198 
Dysmorphic features no yes yes no NR NR NR 
Microcephaly absent moderate moderate absent — — — 
Hypertelorism unknown yes yes no — — — 
Asymmetric face no yes yes no — — — 
Broad nasal bridge no yes yes no — — — 
High arched palate no yes yes no — — — 
Epicanthal folds unknown yes yes no — — — 
Cranial shape normal elongated elongated normal — — — 
Frontal bossing no yes yes moderate — — — 
Low – set ears no yes yes moderate — — — 
Micrognathia no yes yes moderate — — — 
Other        
Genitalia unknown phymosis cryptorchidism no — — reported 
Digital anomalies no no yes no — — — 
Laboratory analyses        
Alkaline phosphatase unknown significantly 
decreased 
decreased no unknown — — 
Lactate dehydrogenase (LDH) increased increased increased no increased — — 
Creatine phosphokinase (CPK) unknown unknown increased normal unknown — — 
a
OMIM number. NR: not reported. Distinctive clinical features are in bold. 
NUBPL, OMIM #252010; an autosomal recessive mitochondrial complex I deficiency characterized by: distinctive leukoencephalopathic 
brain MRI pattern, developmental delay, speech and mobility disability, ataxia, myopathy, nystagmus and absence seizures (Kevelam et 
al, 2013). 
CCDC39, OMIM #613807; an autosomal recessive primary ciliary dyskinesia (PCD) characterized by: neonatal respiratory distress, 
chronic infections of the respiratory tract, rhinosinusitis, situs inversus, situs ambiguous or Kartagener’s syndrome, sperm dysmotility or 
goasthenospermia and infertility (Antony et al, 2013; Merveille et al, 2011). 
DNAJC19, OMIM #610198, 3-methylglutaconic aciduria, type V (MGCA5); an autosomal recessive disorder named dilated 
cardiomyopathy with ataxia (DCMA) characterized by: increase (5 to 10 fold) in urine 3-methylglutaconic acid (3-MGC) and 3-
methylglutaric acid (3-MGA), early-onset dilated cardiomyopathy, long QT syndrome, ECG abnormalities, prenatal or postnatal growth 
failure, non-progressive cerebellar ataxia causing significant motor delays, testicular dysgenesis, isolated cryptorchidism to severe 
perineal hypospadias; normochromic microcytic anaemia, mental retardation and increase in hepatic enzymes and liver steatosis 
(Wortmann et al, 2012). 
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Table S3A. Serum and urine amino acid concentration 
Amino acid 
III:5 - PGK1 c. 358A & t(3;14) III:3 - 
t(3;14) 
III:6 – 
46XY 
II:5 –mother; PGK1 
c.G525A & t(3;14) 
Age-matched 
reference Samp1 Samp 2 Samp 3 
Serum concentrations (μmol/l) 
Alanine 260 157 497 393 534 453 155 - 505 
Arginine 139 121 138 143 167 140 40 -175 
Aspartic acid 95 56 81 127 142 92 30 - 75 
Cysteine ND 56 35 ND ND ND <15 
Citrulline 95 99 75 42 85 77 25 - 55 
Phenylalanine 80 66 58 152 124 91 50 - 130 
Glycine 465 328 413 474 651 541 165 - 585 
Glutamic acid 190 157 151 176 196 150 70 - 190 
Histidine ND 289 167 ND ND ND <135 
Isoleucine 104 98 49 95 114 61 50 - 90 
Leucine 160 113 79 168 191 131 80 - 215 
Lysine 312 421 224 255 294 242 95 - 230 
Methionine 48 82 33 54 63 47 20 - 45 
Ornithine 95 106 93 120 130 100 65 - 180 
Tyrosine 82 107 43 85 112 55 45 - 105 
Tryptophan 117 186 90 141 166 115 50 - 110 
Valine 232 90 114 250 274 204 160 - 315 
Ornitine 95 106 93 120 ND ND 65 - 180 
Urine concentrations (nmol/mol creatinine) 
Alanine 259 19.0 ND 17.0 21.0 36.0 10 - 160 
Arginine 10.0 7.0 ND 2.0 2.0 2.0 <15 
Aspartic acid 21.0 27.0 ND 2.0 3.0 2.0 <15 
Cysteine 23.0 20.0 ND 9.0 7.0 9,0 <10 
Citrulline 10.0 7.0 ND 2.0 2.0 3.0 <8 
Phenylalanine 15.0 15.0 ND 11.0 6.0 10.0 <50 
Glycine 340.0 201.0 ND 82.0 67.0 181,0 50 - 490 
Glutamic acid 157 38.0 ND 5.0 4.0 3.0 <15 
Hydroxyproline 1.0 3.0 ND 0.0 1.0 0,0 <10 
Histidine 379.0 219.0 ND 54.0 125.0 67,0 15 - 180 
Isoleucine 6.0 6.0 ND 2.0 1.0 2.0 <5 
Leucine 9.0 18.0 ND 6.0 4.0 5.0 <10 
Lysine 42.0 32.0 ND 10.0 11.0 10,0 5 - 50 
Methionine 6.0 10.0 ND 1.0 2.0 2,0 <10 
Ornithine 8.0 7.0 ND 1.0 1.0 3,0 <12 
Proline 18.0 19.0 ND 3.0 4.0 3,0 <15 
Tyrosine 17.0 14.0 ND 11.0 5.0 8,0 5 - 40 
Threonine 95.0 114.0 ND 6.0 8.0 20.0 10 - 75 
Tryptophan 30.0 29.0 ND 9.0 8.0 8.0 >20 
Valine 10.0 13.0 ND 3.0 3.0 4.0 >30 
Determination of serum and urine amino acid levels was carried out by liquid chromatography / 
mass spectrometry (LC/MC) using the EZ:Fast amino acid analysis kit (Phenomenex, Torrance, 
CA, USA). 
Samples 1 and 2 of index patient were collected with three months interval during ketogenic diet 
and sample 3 after suspension of ketogenic diet for 5 days. Age-matched reference values for serum 
and urine amino acids concentrations were established from healthy children within the age range of 
6 to 12 and 8 to16 years, respectively. Amino acid levels in the mother are within the normal range 
of age-matched controls. Samp: sample; ND: not done. 
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Table S3B. Urinary organic acid analysis 
Organic acids  
(mmol/mol creatinine) 
III:5 PGK1 c.358A 
& t(3;14) 
Age-matched 
reference 
III:3 - 
t(3;14) 
III:6 
46,XY 
II:5 -
mother 
Samp. 1  Samp. 2     
Adipic acid 19.8 25.2  <5.3 0 0 0 
Uric acid  32.4 ND  <1.5 0 0 0 
Methylmalonic acid 1.5 27.0    0.0 0 0 0 
Suberic acid 12.2 16.3  <8.8 0 0 0 
3-Hydroxysebacic acid  10.4 20.5  <2.0 0 0 0 
3-Hydroxybutyric acid 167.3 1052.2  <7.6 0 0 0 
3-Methylglutaconic acid (3-MGA) 21.9 19.0 <11.4 1.0 0 1.6 
3-Methylglutaric acid (3-MG) 4.5 2.8     0.0 0.4 1.1 0.5 
4-Hydroxyphenyllactic acid  ND 5.0  <3.6 0 0 0 
2-Hydroxybutyric acid ND 14.4  <7.3 0 0 0 
3-Hydroxydicarboxylic acid  ND 6.6    0.0 0 0 0 
Urinary organic acid profiling was carried out by gas chromatography linked mass 
spectrometry (GC/MS) methodology after desalting, ethylacetate extraction and oxime-
trimethylsilyl derivatization of urine samples. 
Samples 1 and 2 were collected with three months interval. Age-matched reference values of 
healthy children within age range 6 - 12 years. Samp: sample; ND: not done. Levels are 
expressed in mmol/mol creatinine. 
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Table S4. Kinetic constants of recombinant PGK1-E120K variant compared to the wild-type 
enzyme 
Results are means (± SE) of 3 determinations from at least 3 different protein preparations. 
Turnover number or kcat, is the number of catalytic events per second, whereas the Michaelis 
constant or Km is the substrate concentration at which the reaction velocity is half maximal and 
kcat/ Km is a measure of how efficiently an enzyme converts substrate to product at sub-saturating 
substrate concentrations. 
 
PGK1 
variants  
Mg-ATP  3-PG 
kcat (s
-1
) Km  (mM) 
kcat / Km  
(s
-1 
mM
-1
) 
 
kcat (s
-1
) Km  (mM) 
kcat / Km  
(s
-1 
mM
-1
) 
        
Wild-type 553.2 ± 28.5 0.28 ± 0.041 1975.7  468.2 ± 33.3 0.17 ± 0.011 2754.1 
p.E120K 7.43 ± 0.55 0.59±   0.062 12.59  4.36 ± 0.98 1.18 ± 0,103 3.7 
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Table S5. Summary of gene expression data obtained by different methods 
a
Expression of genes encompassed within chr3:179357306-182437306 interval; and 
b
within 
chr14:31090249-33050249 interval. 
c
Difference greater than 2 SD. The NUBPL gene disrupted 
by the 3q26.33 breakpoint is in bold. 
d
Statistically significant reduction. 
 
Gene 
symbol 
Assay 
III:3 t(3;14) III:5 
PGK1+t(3;14) 
 Descriptive statistics 
NEL Log2 FC NEL Log2 FC  Average Min Max SD 
PGK1 HuGene-1.0 12.03 0.002 11.78 -0.190  12.0 11.68 12.31 0.192 
3q26.33 region
a
          
USP13 HuGene-1.0 6.72 -0.390 8.13 
c
1.21  7.01 6.56 7.44 0.341 
PEX5L HuGene-1.0 7.63 1.32 5.5 -0.9  6.23 5.16 8.8 1.10 
TTC14 HuGene-1.0 9.14 0.412 8.93 0.157  8.76 8.53 9.08 0.172 
CCDC39 HuGene-1.0 3.36 -0.096 3.35 -0.08  3.42 3.28 3.68 0.130 
FXR1 HuGene-1.0 10.62 -0.099 10.63 -0.01  10.6 10.29 10.89 0.208 
 RT-qPCR NA 1.59 NA 1.60  2.21 1.68 3.25 0.484 
DNAJC19 HuGene-1.0 7.29 -0.014 7.28 -0.016  7.28 7.0 7.56 0.176 
SOX2 HuGene-1.0 5.25 -0.056 4.78 -0.301  5.23 4.89 5.59 0.229 
3q26.33 region
b
          
SCFD1 HuGene-1.0 9.0 -0.241 8.89 -0.391  9.29 8.85 9.72 0.260 
COCH HuGene-1.0 9.35 0.107 9.17 -0.019  9.16 8.21 9.91 0.617 
STRN3 HuGene-1.0 9.07 0.056 9.29 0.122  9.08 8.62 9.37 0.242 
AP4S1 HuGene-1.0 6.21 0.316 5.55 -0.348  5.92 5.41 6.25 0.342 
HECTD1 HuGene-1.0 9.69 0.069 9.63 0.031  9.60 9.32 9.86 0.176 
HEATR5A HuGene-1.0 7.95 0.007 8.04 0.082 0  7.94 6.92 8.93 0.573 
DTD2 & 
C14orf126 
HuGene-1.0 9.01 -0.151 9.17 -0.013  916 8.73 9.75 0.281 
NUBPL HuGene-1.0 7.81 -0.160 7.6 -0.292  7.92 7.62 8.31 0.213 
 RT-qPCR NA 
d
0.058 NA 
d
0.064  0.156 0.115 0.209 0.030 
ARHGAP5 Array 6.49 
c
-1.54 8.14 0.126  8.03 6.48 8.76 0.706 
 RT-qPCR NA 0.130 NA 0.409  0.312 0.108 0.476 0.108 
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Table S6. Expression of nuclear complex I genes in translocation carrier subjects III:3 and III:5 
# 
Gene 
symbol 
Assay 
III:3 t(3;14) III:5 PGK1+t(3;14)  Descriptive statistics 
NEL Log2 FC NEL Log2 FC  Average Min Max SD 
1 NDUFS1 CI core sub.   9.91 -0.027   9.9 -0.003    9.97   9.62 10.43 0.263 
2 NDUFS2 CI core sub. 10.43   0.076 10.47   0.116  10.35 10.09 10.56 0.165 
3 NDUFS3 CI core sub. 10.06 -0.242 10.29 -0.027  10.33 10.01 10.62 0.209 
4 NDUFS7 CI core sub.   8.17 -0.226   8.35 -0.087    8.41   8.17   8.72 0.186 
5 NDUFS8 CI core sub.   8.81   0.156   8.97   0.331    8.65   8.43   8.94 0.169 
6 NDUFV1 CI core sub. 10.41 -0.007 10.39 -0.006  10.40 10.33 10.51 0.056 
7 NDUFV2 CI core sub.   8.54 -0.076   8.62 -0.011    8.64   7.66   9.92 0.681 
8 NDUFA1 CI sup. sub. 10.20 -0.133 10.32 -0.018  10.33   9.97 10.56 0.202 
9 NDUFA2 CI sup. sub. 10.37 -0.048 10.42 -0.001  10.44 10.06 10.66 0.170 
10 NDUFA3 CI sup. sub. 10.5 -0.036 10.38 -0.044  10.51 10.03 10.76 0.260 
11 NDUFA4 CI sup. sub.   8.26 -0.107   8.49   0.128    8.44   7.82   8.7 0.313 
12 NDUFA5 CI sup. sub.   8.57   0.026   8.46 -0.021    8.62   7.9   9.25 0.386 
13 NDUFA6 CI sup. sub. 10.22 -0.105 10.38   0.005  10.42   9.98 10.83 0.266 
14 NDUFA7 CI sup. sub. 10.22 -0.225 10.58   0.166  10.37 10.12 10.66 0.179 
15 NDUFA8 CI sup. sub.   9.34 -0.101   9.59   0.151    8.98   8.98   9.67 0.235 
16 NDUFA9 CI sup. sub. 10.33 -0.031 10.39 -0.006  10.26   9.97 10.68 0.215 
17 NDUFA10 CI sup. sub.   9.96 
a
-0.447 10.42   0.030  10.38 10.15 10.67 0.174 
18 NDUFA11 CI sup. sub.   7.96 -0.287   8.34   0.110    8.24   7.89   8.74 0.295 
19 NDUFA12 CI sup. sub. 10.87   0.088 10.81   0.032  10.83 10.54 11.03 0.157 
20 NDUFA13 CI sup. sub.   8.27 -0.022   8.5   0.221    8.28   8.15   8.59 0.139 
21 NDUFAB1 CI sup. sub.   9.11 -0.095   9.2   0.032    9.21   8.7   9.66 0.327 
22 NDUFB1 CI sup. sub.   7.66 -0.113   7.73 -0.005    7.71   7.35   8.04 0.233 
23 NDUFB2 CI sup. sub.   9.22   0.013   9.34   0.091    9.19   8.85   9.53 0.216 
24 NDUFB3 CI sup. sub.   5.63 -0.306   5.86   0.033    5.82   5.2   6.27 0.338 
25 NDUFB4 CI sup. sub. 10.44 -0.246 10.56 -0.113  10.68 10.16 10.99 0.272 
26 NDUFB5 CI sup. sub. 11.07 -0.131 11.3   0.063  11.23 10.87 11.58 0.251 
27 NDUFB6 CI sup. sub.   7.98   0.036   8.06   0.106    7.93   7.22   8.56 0.425 
28 NDUFB7 CI sup. sub.   8.31 -0.140   8.49   0.061    8.44   8.23   8.8 0.177 
29 NDUFB8 CI sup. sub. 11.44 -0.087 11.5 -0.053  11.56 11.37 11.77 0.148 
30 NDUFB9 CI sup. sub.   9.53 -0.236   9.72   0.088    9.74   9.47 10.07 0.189 
31 NDUFB10 CI sup. sub.   9.1 -0.178   9.48   0.185    9.29   9.03   9.71 0.240 
32 NDUFB11 CI sup. sub. 10.53 -0.231 10.53 -0.240  10.80 10.57 11.21 0.229 
33 NDUFC1 CI sup. sub.   9.19   0.033   9.11   0.057    9.11   8.61   9.55 0.296 
34 NDUFC2 CI sup. sub. 10.73 -0.076 10.69 -0.106  10.80 10.18 11.11 0.302 
35 NDUFS4 CI sup. sub.   8.67 -0.016   8.55 -0.027    8.67   8.18   9.03 0.277 
36 NDUFS5 CI sup. sub. 11.9 -0.103 12.16   0.156  12.0 11.73 12.25 0.166 
37 NDUFS6 CI sup. sub.   8.57 -0.174   8.96   0.248    8.71   8.25   9.13 0.302 
38 NDUFV3 CI sup. sub.   9.1   0.030   9.05   0.016    9.03   8.9   9.26 0.106 
39 NDUFAF1 CI ass. fact.   7.63   0.195   7.14 -0.156    7.32   6.57   7.88 0.493 
40 NDUFAF2 CI ass. fact.   6.64 
a
-0.457   7.09 -0.138    7.12   6.84   7.36 0.144 
41 NDUFAF3 CI ass. fact.   9.98 0.303 10.08 0.121    9.84   9.53 10.04 0.164 
42 NDUFAF4 CI ass. fact.   9.34   0.168   9.28   0.068    9.20   8.75   9.66 0.376 
43 NDUFAF5 
C20ORF7 
CI ass. fact. 7.23 0.030 6.75 -0.001    7.01   6.64   7.37 0.275 
44 NDUFAF6 
C8ORF38 
CI ass. fact. 5.44 -0.174 5.84 0.046    5.63   5.07   6.36 0.377 
45 AIFM1 CI ass. fact.   9.15 -0.178   9.38   0.068    9.41   8.97   9.77 0.243 
46 ECSIT CI ass. fact.   8.22 -0.22   8.23 -0.092    8.39   8.26   8.6 0.126 
47 FOXRED1 CI ass. fact.   9.07 0.093   8.74 -0.082    8.75   8.43   9.48 0.374 
48 PHB CI ass. fact. 10.42 -0.216 10.33 -0.278  10.56   9.89 11.06 0.325 
49 PTCD1 CI ass. fact.   7.83 -0.008   7.67 -0.153    7.82   7.72   8.03 0.096 
50 NUBPL CI ass. fact.   7.81 -0.160   7.6 -0.292    7.92   7.62   8.31 0.213 
Include 7 CI core subunits (#1-7), 31 CI supernumerary subunits (#8-38), and 12 CI assembly 
factors (#39-46) (according to [Fassone and Rahman 2012; Calvo et al, 2010). NEL 
normalized expression level. Translocation carriers were compared individually to a control group. 
a
Difference greater than 2 SD. 
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Table S7. Main interactions of the amino acid involved in the mutation. 
Residue 
Open conformation
a
  Closed conformation
b
 
Hydrogen/ionic 
interactions 
Hydrophobic 
interactions 
Solvent 
accessible
c 
 Hydrogen/ionic 
interactions 
Hydrophobic 
interactions 
Solvent 
accessible
c 
E120       yes  
OE1 
OE2 
→S77 
→L78 
OG 
N 
   yes 
Residue E120 is solvent accessible and in the closed conformation of the protein makes 
hydrogen bonds with Ser77 and Leu78 of the loop connecting β-strand B with the helix 2 
(Fig. S5). 
a
Atomic coordinates of Protein Data Bank entry 2XE7; 
b
atomic coordinates of 
Protein Data Bank entry 2WZC; 
c
calculated with the CCP4 Suite, residues are considered 
solvent accessible when accessible surface area is > 5 Å. 
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